KYMR vs BBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KYMR · Kymera Therapeutics$131.73 ▲ 2.82%
BBIO · BridgeBio Pharma$74.29 ▲ 0.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KYMR +115.0%
- BBIO +18.3%
Head to head
| Metric | KYMR | BBIO |
|---|---|---|
| Price | $131.73 | $74.29 |
| Change today | ▲ 2.82% | ▲ 0.03% |
| Market cap | $11.25B | $14.47B |
| Return, 3 months | +21.3% | -12.3% |
| Return, year to date | +69.3% | -2.9% |
| Return, 1 year | +124.6% | +20.2% |
| P/E (TTM) | – | – |
| P/B | 7.0 | -5.6 |
| P/E percentile vs own 5y | 3rd | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | +120.4% |
| Net profit growth (YoY) | -60.6% | +15.2% |
| Gross margin | – | 94.4% |
| Operating margin | -396.0% | -67.0% |
| Net margin | -341.8% | -97.0% |
| Return on equity | -27.3% | – |
| Analyst target vs. price | +9.2% | +47.7% |
| Analyst buy share | 94% | 94% |
| RSI (14) | 65 | 60 |
| 30-day volatility | 46.3% | 35.2% |
| Max drawdown, 1 year | -27.7% | -29.8% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBIO is the largest of the group by market value.
- KYMR has returned the most over the past year.
- BBIO is growing revenue fastest.
- BBIO keeps the most profit per dollar of sales.
- BBIO has been the calmest stock over the last 30 days.